Ann Rheum Dis

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER


[Advanced]
Published Online First: 31 July 2006. doi:10.1136/ard.2006.052761
Annals of the Rheumatic Diseases 2006;65:1406-1413
Copyright © 2006 BMJ Publishing Group Ltd & European League Against Rheumatism
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
ard.2006.052761v1
65/11/1406    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lodde, B M
Right arrow Articles by Illei, G
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lodde, B M
Right arrow Articles by Illei, G

REVIEW

Experience with experimental biological treatment and local gene therapy in Sjögren’s syndrome: implications for exocrine pathogenesis and treatment

B M Lodde 1,2, B J Baum 1, P P Tak 2, G Illei 1

1 Gene Therapy and Therapeutics Branch/NIDCR, National Institutes of Health, DHHS, Bethesda, Maryland, USA
2 Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, The Netherlands

Correspondence to:
Correspondence to:
G Illei
Gene Therapy and Therapeutics Branch/NIDCR, National Institutes of Health, 10 Center Drive, Building 10, Room 1N114, Bethesda, MD 20892-1190, USA; gillei{at}mail.nih.gov


ABSTRACT
Sjögren’s syndrome is an autoimmune exocrinopathy, mainly affecting the lacrimal and salivary glands, and resulting in ocular and oral dryness (keratoconjunctivitis sicca and xerostomia). The aetiology and pathogenesis are largely unknown, and only palliative treatment is currently available. Data obtained from experimental animal and human studies using biological agents or gene therapeutics can offer insight into the disease process of Sjögren’s syndrome. This article reviews the current literature on these approaches and assesses the lessons learnt about the pathogenesis of Sjögren’s syndrome.

Abbreviations: AAV, adeno-associated virus; BAFF, B cell-activating factor; FasL, Fas ligand; IFN, interferon; MALT, mucosa-associated lymphoid tissue; NF{kappa}B, nuclear factor {kappa}B; NOD, non-obese diabetic; rAAV2, recombinant serotype 2 AAV vector; RANTES, regulated on activation, normal T cell expressed and secreted; SMG, submandibular gland; TNF, tumour necrosis factor; TNFRp55-Ig, human 55-kDa TNF receptor extracellular domain linked to a mouse IgG heavy chain; VIP, vasoactive intestinal peptide






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2006 BMJ Publishing Group Ltd & European League Against Rheumatism